This approval converts RVMD from a pure-play clinical-stage biotech to a commercial-stage company with a priced product. Monitor initial prescription volumes, payer coverage decisions, and any competitor RAS inhibitor developments. The high market cap already reflects substantial optimism, but the data and pricing support a multi-billion peak sales opportunity if RASONQUE delivers meaningful survival benefit.
Drug in focus
RVMD drug pipeline →daraxonrasib
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3 (completed with positive results) / pre-NDA
- Time to market
- NDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed
- Next catalyst
- None dated
What to watchDaraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 26 $215.44entry
- T+1 · 3mo ago +2.65%α +2.00% · $221.15
- T+5 · 3mo ago −2.88%α −2.76% · $209.23
- T+20 · 8w ago −7.23%α −7.46% · $199.86
- T+57 · todayOpen
- T+60 · in 2d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines announced FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma on August 26, 2026, based on Phase 3 RASolute 302 data. The oral therapy is now available in the U.S. with a wholesale acquisition cost of $39,800 per 30-day supply. This is a transformative milestone for the company, converting its lead pipeline asset to a commercial product in a large unmet-need indication.
Key Facts
- FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or when multiagent therapy is not an option.
- Approval based on Phase 3 RASolute 302 trial vs. investigator's choice chemotherapy.
- Once-daily oral tablets immediately available for prescribing in the U.S.
- Wholesale acquisition cost is $39,800 for a 30-day supply at the recommended dose.
- Company is Revolution Medicines, Inc. (ticker: RVMD), a late-stage biotech with a $45.3B market cap.
Financial Impact
First approved product, pricing at ~$39,800/month. For a pancreatic cancer indication with estimated ~60,000 new U.S. cases/year (of which ~80% are metastatic), even capturing 5-10% of the eligible second-line-plus population could represent annualized revenue in the hundreds of millions to low billions, subject to label uptake, competition, and reimbursement.
Risk Factors
- Competition from other RAS pathway inhibitors (e.g., Amgen's Lumakras, Mirati's Krazati, or future pan-RAS drugs) could limit market share.
- Reimbursement and formulary access for a high-priced oral oncolytic may be slow in the second-line+ pancreatic setting.
- Pancreatic adenocarcinoma is a difficult-to-treat cancer; real-world survival data may not fully replicate trial results.
- Stock already at $45B market cap, priced for substantial commercial success, leaving limited upside if uptake disappoints.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-366931 |
| Document: 0001193125-26-366931-index.html | 0001193125-26-366931 |
| Document: 0001193125-26-366931.txt | 0001193125-26-366931 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers